PTK2 and ovarian cancer: Our current study suggests that disrupting the integrin–FAK signaling has a limited impact on the paclitaxel resistance of ovarian cancer, consistent with a prior study.42 Yet, this observation differs from a recent analysis with an FAK inhibitor.19 The precise reason behind such discrepancy currently remains unclear.